Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 13/20 | 0.60 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.60 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.60 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.60 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.60 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.60 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581650 | 0.91 | DRD4 (0.56) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4580918 | 0.90 | PRKAA2 (0.54) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4581243 | 0.85 | PRKAA2 (0.52) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4580286 | 0.81 | PRKAA2 (0.58) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL15743029 | 0.78 | CNR1 (0.54) | — | |
| SCHEMBL519372 | 0.76 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL7239441 | 0.75 | CCR3 (0.72) | SLC6A12DRD4SIGMAR1 | |
| SCHEMBL15741561 | 0.75 | HPGD (0.50) | — | |
| SCHEMBL18024447 | 0.75 | CKS1B (0.51) | — | |
| SCHEMBL518027 | 0.73 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
| WO-2014079787-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | PRKAA2 4491/4885PRKAB2 4072/4885PRKAG1 4025/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | PRKAA2 4491/4885PRKAB2 4072/4885PRKAG1 4025/4885 |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | CBR3, CBR1, NR2C2 | PRKAA2 2564/4885PRKAB2 4561/4885PRKAG1 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.